A2 Bio Announces Oral and Poster Presentations at the 2023 Society for Immunotherapy of Cancer (SITC) Annual Meeting

On October 16, 2023 A2 Biotherapeutics, Inc. (A2 Bio) a clinical-stage cell therapy company developing first-in-class logic-gated cell therapies for solid tumors, reported an oral presentation and two poster presentations of trial-in-progress data from their pre-screening (BASECAMP-1) and first-in-human Phase 1 study (EVEREST-1) at the 38th Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) Annual Meeting November 1-5, 2023, in San Diego, CA (Press release, A2 Biotherapeutics, OCT 16, 2023, View Source [SID1234636040]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Oral presentation

BASECAMP-1: A master prescreening study to identify patients with high-risk or metastatic solid tumors with HLA loss of heterozygosity (LOH) in preparation for Tmod CAR T-cell therapy trials
Presenter: Diane Simeone, MD – NYU
Session: Rapid Oral Abstract-Clinical | Session 105b
Date and time: Friday, November 3; 12:15pm – 1:15pm PT
Location: Ground Level – Exhibit Hall C – San Diego Convention Center

Poster presentations

EVEREST-1: A seamless phase 1/2 study of CEA logic-gated Tmod CAR T-cell therapy (A2B530) in patients with solid tumors associated with CEA expression also exhibiting HLA loss of heterozygosity (LOH)
Abstract: 634
Presenter: Salman Punekar, MD – NYU
Date and time: Saturday, November 4, 2023; 9am – 8:30pm PT
Location: Exhibit Halls A and B1 – San Diego Convention Center

BASECAMP-1: A master prescreening study to identify patients with high-risk or metastatic solid tumors with HLA loss of heterozygosity (LOH) in preparation for Tmod CAR T-cell therapy trials
Abstract: 636
Presenter: Diane Simeone, MD – NYU
Date and time: Saturday, November 4, 2023; 9am – 8:30pm PT
Location: Exhibit Halls A and B1 – San Diego Convention Center